Prostate adenocarcinoma
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DIS-PROSTATE |
|---|---|
| Type | Disease |
| Aliases | PCaProstate cancerАденокарцинома передміхурової залозиРПЗ |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-EAU-PROSTATE-2024 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.
| icd_o_3_morphology | 8140/3 |
|---|---|
| icd_o_3_topography | ["C61.9"] |
| icd_10 | C61 |
| who_classification | Acinar adenocarcinoma of the prostate (WHO 5th) |
Notes
Coverage scope MVP: advanced disease (mHSPC + mCRPC + nmCRPC). Localized disease (active surveillance, RP, definitive RT, brachytherapy) intentionally out of scope — would require urology workflow modeling beyond current architecture.
Used By
Actionability
BMA-ATM-GERMLINE-PROSTATE- ATM germline pathogenic in mCRPC: olaparib approved per PROfound (Cohort A included ATM);...BMA-ATM-SOMATIC-PROSTATE- Somatic ATM loss-of-function in mCRPC: PROfound enrolled both germline and somatic ATM in...BMA-BRCA1-GERMLINE-PROSTATE- BRCA1 germline pathogenic in mCRPC: olaparib improves rPFS and OS post-NHA (PROfound Coho...BMA-BRCA1-SOMATIC-PROSTATE- Somatic BRCA1 loss-of-function in mCRPC: PROfound enrolled both germline and somatic; ola...BMA-BRCA2-GERMLINE-PROSTATE- BRCA2 germline pathogenic in mCRPC: largest PARPi benefit in HRR pathway (PROfound Cohort...BMA-BRCA2-SOMATIC-PROSTATE- Somatic BRCA2 loss-of-function in mCRPC: PROfound included sBRCA; olaparib benefit equiva...BMA-CHEK1-SOMATIC-PROSTATE- Somatic CHEK1 loss-of-function in mCRPC: rare; PROfound included CHEK1 in Cohort B but sm...BMA-CHEK2-GERMLINE-PROSTATE- CHEK2 germline pathogenic in mCRPC: included in PROfound Cohort B; olaparib FDA HRR label...BMA-CHEK2-SOMATIC-PROSTATE- Somatic CHEK2 in mCRPC: PROfound enrolled both g/s; FDA olaparib HRR label includes CHEK2...BMA-HRD-STATUS-PROSTATE- Homologous-recombination-repair (HRR) gene alterations in metastatic castration-resistant...BMA-MLH1-GERMLINE-PROSTATE- MLH1 germline loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-...BMA-MLH1-SOMATIC-PROSTATE- MLH1 somatic loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH2-GERMLINE-PROSTATE- MSH2 germline loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-...BMA-MSH2-SOMATIC-PROSTATE- MSH2 somatic loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-MSH6-GERMLINE-PROSTATE- MSH6 germline loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-...BMA-MSH6-SOMATIC-PROSTATE- MSH6 somatic loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-PIK3CA-HOTSPOT-PROSTATE- PIK3CA mutations rare in prostate (~5%); PI3K/AKT/mTOR pathway often activated via PTEN l...BMA-PMS2-GERMLINE-PROSTATE- PMS2 germline loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-...BMA-PMS2-SOMATIC-PROSTATE- PMS2 somatic loss-of-function in prostate produces dMMR/MSI-H phenotype. Pan- tumor MSI-H...BMA-PSA-PROSTATE-USPSTF-SHARED-DECISION- PSA screening for prostate cancer carries a USPSTF Grade C recommendation for men aged 55...BMA-TP53-MUT-PROSTATE- TP53 mutation in PROSTATE — common, adverse prognostic; not directly targeted. Per usual...
Algorithms
ALGO-AMSTERDAM-II-LYNCH- ALGO-AMSTERDAM-II-LYNCHALGO-BOADICEA-V6-BREAST-OVARIAN- ALGO-BOADICEA-V6-BREAST-OVARIANALGO-BRCAPRO- ALGO-BRCAPROALGO-HEREDITARY-PROSTATE-CANCER-RISK- ALGO-HEREDITARY-PROSTATE-CANCER-RISKALGO-MANCHESTER-BRCA- ALGO-MANCHESTER-BRCAALGO-PREMM5-LYNCH- ALGO-PREMM5-LYNCHALGO-PROSTATE-MCRPC-1L- ALGO-PROSTATE-MCRPC-1LALGO-PROSTATE-MCRPC-2L- ALGO-PROSTATE-MCRPC-2LALGO-PROSTATE-MHSPC-1L- ALGO-PROSTATE-MHSPC-1L
Handbook Chapters
HB-PROSTATE-MCRPC-1L- Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning
Indication
IND-PROSTATE-MCRPC-1L-ARPI- IND-PROSTATE-MCRPC-1L-ARPIIND-PROSTATE-MCRPC-1L-PARPI- IND-PROSTATE-MCRPC-1L-PARPIIND-PROSTATE-MCRPC-2L-CABAZITAXEL- IND-PROSTATE-MCRPC-2L-CABAZITAXELIND-PROSTATE-MCRPC-2L-DOCETAXEL- IND-PROSTATE-MCRPC-2L-DOCETAXELIND-PROSTATE-MCRPC-2L-LU-PSMA- IND-PROSTATE-MCRPC-2L-LU-PSMAIND-PROSTATE-MCRPC-2L-PARPI- IND-PROSTATE-MCRPC-2L-PARPIIND-PROSTATE-MCRPC-2L-RADIUM223- IND-PROSTATE-MCRPC-2L-RADIUM223IND-PROSTATE-MHSPC-1L-ARPI-DOUBLET- IND-PROSTATE-MHSPC-1L-ARPI-DOUBLETIND-PROSTATE-MHSPC-1L-TRIPLET- IND-PROSTATE-MHSPC-1L-TRIPLET
Questionnaires
QUEST-PROSTATE-1L-STUB- Prostate adenocarcinoma — first line
Red flag
RF-ATM-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic monoallelic variant in ATM (heterozygou...RF-ATM-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline ATM heterozygous carrier state in an asymp...RF-BRCA-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in BRCA1 or BRCA2 — the canonic...RF-BRCA-HBOC-FAMILY-HISTORY-SUSPICION- Family pedigree meeting criteria suggestive of Hereditary Breast and Ovarian Cancer (HBOC...RF-CASCADE-BRCA-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CASCADE-FAP-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CASCADE-LYNCH-FDR-POSITIVE- A first-degree relative of the patient (parent, sibling, or child) has a documented posit...RF-CHAARTED-HIGH-VOLUME-MHSPC- Metastatic hormone-sensitive prostate cancer meeting CHAARTED high-volume criteria — visc...RF-CHEK2-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic monoallelic variant in CHEK2. Most comm...RF-CHEK2-FAMILY-HISTORY-SUSPICION- Family pedigree pattern suggestive of germline CHEK2 heterozygous carrier state in an asy...RF-FAP-FAMILY-HISTORY-SUSPICION- Family pedigree suggestive of Familial Adenomatous Polyposis (FAP) or the attenuated FAP...RF-LATITUDE-HIGH-RISK-MHSPC- Metastatic hormone-sensitive prostate cancer meeting LATITUDE high-risk criteria — ≥2 of...RF-LYNCH-CONFIRMED-CARRIER- Confirmed germline pathogenic / likely-pathogenic variant in a Lynch syndrome (MMR / EPCA...RF-LYNCH-FAMILY-HISTORY-SUSPICION- Family pedigree meeting criteria suggestive of hereditary nonpolyposis colorectal cancer...RF-PAN-ATM-CHEK2-CDK12-PARPI-CANDIDATE- Germline pathogenic variant in ATM, CHEK2, or CDK12 (composite HRR-pathway RF). Disease-s...RF-PAN-BRCA-SOMATIC-PARPI-CANDIDATE- Somatic (tumor-only) BRCA1 or BRCA2 pathogenic variant identified on tumor NGS — pan-tumo...RF-PAN-PALB2-PARPI-CANDIDATE- Germline PALB2 pathogenic variant — BRCA2's recruitment partner; biallelic LOF produces a...RF-PROSTATE-AR-AMP-ARSI-RESISTANCE- AR (androgen receptor) gene amplification detected on tumor or ctDNA NGS in mCRPC — INFOR...RF-PROSTATE-AR-V7-ARSI-RESISTANCE- AR-V7 (androgen receptor splice variant 7) detected in CTCs / ctDNA in mCRPC — predictive...RF-PROSTATE-CORD-COMPRESSION- Metastatic prostate cancer with malignant epidural spinal cord compression (MESCC): new m...RF-PROSTATE-FRAILTY-AGE- Age ≥80 OR ECOG ≥3 with significant comorbidity — docetaxel poorly tolerated; ARPI monoth...RF-PROSTATE-HIGH-RISK-BIOLOGY- Germline or somatic BRCA1/2 mutation OR broader HRR pathway alteration (ATM, CDK12, PALB2...RF-PROSTATE-INFECTION-SCREENING- Pre-treatment HBV/HCV/HIV serology + dental evaluation (denosumab/zoledronate ONJ risk; l...RF-PROSTATE-ORGAN-DYSFUNCTION- Renal dysfunction (CrCl <50 mL/min) or severe hepatic impairment (Child-Pugh C) — limits...RF-PROSTATE-PSA-PROGRESSION- PCWG3-defined PSA progression on systemic prostate-cancer therapy: ≥25% rise from nadir +...RF-PROSTATE-TMPRSS2-ERG-PROGNOSTIC- TMPRSS2-ERG fusion detected on tumor RNA / FISH / IHC for ERG in localized or metastatic...RF-PROSTATE-TRANSFORMATION-PROGRESSION- Spinal cord compression OR rapid PSA doubling time (<3 months) OR new visceral metastases...
Regimen
REG-CABAZITAXEL-MCRPC- Cabazitaxel (mCRPC, 2L)REG-DOCETAXEL-MCRPC- Docetaxel (mCRPC)REG-RADIUM223-MCRPC- Radium-223 (mCRPC, bone-metastatic)
Sources
SRC-ARASENS-SMITH-2022- Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate CancerSRC-CHAARTED-SWEENEY-2015- Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerSRC-EAU-PROSTATE-2024- EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate CancerSRC-ENZAMET-DAVIS-2019- Enzalutamide with Standard First-Line Therapy in Metastatic Prostate CancerSRC-ESMO-PROSTATE-2024- ESMO Clinical Practice Guideline on Prostate CancerSRC-LATITUDE-FIZAZI-2017- Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate CancerSRC-NCCN-PROSTATE-2025- NCCN Clinical Practice Guidelines — Prostate CancerSRC-PCPT-FINASTERIDE-2003- The influence of finasteride on the development of prostate cancer (Prostate Cancer Preve...SRC-PROFOUND-DEBONO-2020- Olaparib for Metastatic Castration-Resistant Prostate CancerSRC-REDUCE-DUTASTERIDE-2010- Effect of dutasteride on the risk of prostate cancer (REDUCE — Reduction by Dutasteride o...SRC-TALAPRO2-AGARWAL-2023- Talazoparib plus Enzalutamide in Men with First-Line Metastatic Castration-Resistant Pros...SRC-TAX327-TANNOCK-2004- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerSRC-VISION-PSMA-SARTOR-2021- Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate CancerSRC-VITAL-VITAMIN-D-OMEGA3-2019- Vitamin D supplements and prevention of cancer and cardiovascular disease (VITAL — Vitami...